CALR mutation screening in pediatric primary myelofibrosis-Reference-Cited by-同舟云学术

CALR mutation screening in pediatric primary myelofibrosis

Published:2014-08-30 Issue:12 Volume:61 Page:2256-2262
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

An Wenbin¹²,Wan Yang¹²,Guo Ye¹,Chen Xiaojuan¹,Ren Yuanyuan¹²,Zhang Jingliao¹²,Chang Lixian¹²,Wei Wei¹²,Zhang Peihong³,Zhu Xiaofan¹²

Affiliation:

1. Pediatric Blood Diseases Centre; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College; Tianjin China

2. State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College; Tianjin China

3. Department of Pathology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College; Tianjin China

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference44 articles.

1. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs;Rollison;Blood,2008

2. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders;Greiner;Am J Clin Pathol,2006

3. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients;Pardanani;Blood,2006

4. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1;Tefferi;Leukemia,2010

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloproliferative Neoplasms (MPNs);Pediatric Pathology of Hematopoietic and Histiocytic Disorders;2024-02-15

2. Myeloproliferative Disorders in Non-Down Syndrome Patients;Pediatric Oncology;2024

3. Myeloproliferative Neoplasms;Atlas of Pediatric Hematopathology;2023-07-13

4. Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity;Frontiers in Pediatrics;2022-11-07

5. Pediatric myelofibrosis due to compound heterozygous MPIG6B mutations in a patient of European ancestry;Pediatric Blood & Cancer;2022-10-02